ABT Quote, Financials, Valuation and Earnings

Edwards Lifesciences Corp. has a net margin of 14.07% compared to Abbott Laboratories's net margin of 18.82%. Abbott Laboratories's return on equity of 29.06% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.36%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $95.80 which suggests that it could grow by 11.1%. Given that Abbott Laboratories has higher upside potential than Edwards Lifesciences Corp., analysts believe Abbott Laboratories is more attractive than Edwards Lifesciences Corp..

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.229%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.9%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are larger than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Abbott Laboratories's net income of $1.6B is higher than Edwards Lifesciences Corp.'s net income of $292.3M. Notably, Abbott Laboratories's price-to-earnings ratio is 15.62x while Edwards Lifesciences Corp.'s PE ratio is 36.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.97x versus 8.62x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 14.07% compared to Abbott Laboratories's net margin of 28.31%. Abbott Laboratories's return on equity of 29.06% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.36%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.86%. Given that Abbott Laboratories has higher upside potential than Intuitive Surgical, Inc., analysts believe Abbott Laboratories is more attractive than Intuitive Surgical, Inc..

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.9%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Abbott Laboratories's net income of $1.6B is higher than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Abbott Laboratories's price-to-earnings ratio is 15.62x while Intuitive Surgical, Inc.'s PE ratio is 76.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.97x versus 21.84x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 14.07% compared to Abbott Laboratories's net margin of 26.1%. Abbott Laboratories's return on equity of 29.06% beat ResMed, Inc.'s return on equity of 25.6%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.36%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.3%. Given that ResMed, Inc. has higher upside potential than Abbott Laboratories, analysts believe ResMed, Inc. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.9%. ResMed, Inc. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.60 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are larger than ResMed, Inc. quarterly revenues of $1.3B. Abbott Laboratories's net income of $1.6B is higher than ResMed, Inc.'s net income of $348.5M. Notably, Abbott Laboratories's price-to-earnings ratio is 15.62x while ResMed, Inc.'s PE ratio is 25.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.97x versus 6.85x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 14.07% compared to Abbott Laboratories's net margin of 14.18%. Abbott Laboratories's return on equity of 29.06% beat Stryker Corp.'s return on equity of 14.06%.

Abbott Laboratories has a consensus price target of $144.43, signalling upside risk potential of 15.36%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 20.66%. Given that Stryker Corp. has higher upside potential than Abbott Laboratories, analysts believe Stryker Corp. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.716, which suggesting that the stock is 28.412% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.9%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. Abbott Laboratories pays 29.33% of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.4B, which are larger than Stryker Corp. quarterly revenues of $6.1B. Abbott Laboratories's net income of $1.6B is higher than Stryker Corp.'s net income of $859M. Notably, Abbott Laboratories's price-to-earnings ratio is 15.62x while Stryker Corp.'s PE ratio is 46.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.97x versus 5.62x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.